Chromium for Type 2 Diabetes

Verdict: Weak, conflicting evidence; not recommended

The evidence that chromium supplements meaningfully control blood sugar in type 2 diabetes is weak and conflicting. Any effect on glucose markers is small at best, was not reproduced in well-conducted Western trials, and major diabetes authorities do not recommend chromium as a treatment.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The trial record is inconsistent. An early Chinese study (PMID 9356027) reported a striking HbA1c drop of about 1.9% on high-dose chromium, but this result is an outlier most likely tied to baseline deficiency and was never reproduced. In a Western randomized trial of chromium yeast, there was no effect on HbA1c at all (PMID 17303791).

Meta-analyses temper the picture further. A 2014 review of 25 trials (PMID 24635480) found only a modest, highly heterogeneous HbA1c reduction of roughly 0.55%, driven mainly by chromium picolinate above 200 mcg/day. A 2015 meta-analysis (PMID 25971249) found no significant HbA1c benefit for any form and only a minor fasting-glucose effect for brewer's yeast, and an NIH systematic review (PMID 27261273) concluded just 3 of 14 trials hit a clinically meaningful target. All outcomes are surrogate markers, with no data on complications or mortality.

Regulators and clinics largely agree. The FDA calls any link 'highly uncertain' and the EU's EFSA found 'no evidence of beneficial effects,' while NIH ODS judges chromium's effects to be of 'little clinical significance' and Cleveland Clinic advises caution given drug interactions and scant upside. The American Diabetes Association states there is insufficient evidence to support routine chromium use. Hence a weak, disputed grade: chromium is not a reliable treatment and should not replace standard diabetes care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
70%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.32
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.427
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes
PMID: 9356027 1997 RCT (double-blind) n = 180
Finding: Chinese cohort: HbA1c fell from 8.5% (placebo) to 6.6% in 1000 mcg/day group at 4 months; fasting and 2-h insulin decreased in both chromium groups; plasma cholesterol improved in high-dose group. Large effect not replicated in Western populations.
Government Effect size: HbA1c MD ~ -1.9% (high-dose vs placebo) — outlier vs later Western trials
View on PubMed
Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial
PMID: 17303791 2007 RCT (double-blind) n = 57
Finding: No significant difference in HbA1c between chromium and placebo; no effect on lipids, BMI, blood pressure, or insulin requirements. Authors conclude chromium yeast is not effective for glycemic control in Western T2DM patients on OHAs.
🟢 High quality Academic Effect size: HbA1c MD ~ 0 (NS)
View on PubMed
Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes
PMID: 24635480 2014 統合分析
Finding: 25 RCTs. HbA1c MD -0.55% (95% CI -0.88 to -0.22, p=0.001) and FPG MD -1.15 mmol/L (95% CI -1.84 to -0.47, p=0.001) favoring chromium; chromium picolinate and doses >200 mcg/day drove the effect. Heterogeneity acknowledged; safety comparable to placebo at usual doses.
Academic Effect size: HbA1c MD -0.55%; FPG MD -1.15 mmol/L (~ -20.7 mg/dL)
View on PubMed
Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness
PMID: 27261273 2016 系統性回顧
Finding: Only 3/14 trials reaching HbA1c <=7% and 5/14 with >=0.5% HbA1c decline. Authors (NIH ODS) conclude chromium supplements have limited effectiveness and there is little rationale to recommend them for glycemic control in existing T2DM — consistent with ADA Standards of Care, which do not recommend chromium.
🟢 High quality Government Effect size: Most trials below clinically meaningful threshold
View on PubMed
Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus
PMID: 25971249 2015 統合分析 n = 875
Finding: No statistically significant effect on HbA1c for chromium yeast, brewer's yeast, or chromium picolinate. Only brewer's yeast showed FPG reduction (MD -19.23 mg/dL) vs placebo. Authors conclude chromium offers at most marginal FPG benefit and no HbA1c benefit.
Effect size: HbA1c NS across forms; FPG MD -19.23 mg/dL only for brewer's yeast
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain. source↗
L4b EU EFSA
Against
The Panel concludes that there is no evidence of beneficial effects associated with chromium intake in healthy subjects ... no Average Requirement (AR) and Population Reference Intake (PRI) can be defined; chromium is not an essential nutrient. source↗
L4c UK NHS
Cautious
You should be able to get all the chromium you need by eating a varied and balanced diet. Around 25 micrograms of chromium a day should be enough for adults. Having 10mg or less a day of chromium from food and supplements is unlikely to cause any harm. source↗
L4d TW TFDA / 衛福部
Supportive
每日食用量中,其鉻之總含量不得高於200微克 source↗
L4e WHO
Not addressed
Chromium[VI] is carcinogenic to humans (Group 1). Metallic chromium and chromium[III] compounds are not classifiable as to their carcinogenicity to humans (Group 3). source↗
L5a NIH Office of Dietary Supplements
Cautious
Research suggests that chromium supplementation reduces body weight and body fat percentage to a very small, but statistically significant, extent. However, these effects have little clinical significance. source↗
L5b Mayo Clinic
Cautious
There is evidence that shows chromium can decrease fasting blood glucose, insulin levels, and hemoglobin A1C (HbA1C), and can increase insulin sensitivity in people with type 2 diabetes. source↗
L5c Cleveland Clinic
Cautious
I'd advise a lot of caution with using chromium supplements. There is a risk of interactions with some medications and potential negative side effects — and not enough evidence that there's an upside. source↗
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Against
There is insufficient evidence to support the routine use of herbal supplements and micronutrients, such as cinnamon, curcumin (e.g., turmeric), aloe vera, or chromium, to improve glycemia in people with type 1 or type 2 diabetes. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-chromium-001 繁體中文版 →